Brief: Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13/05/2024 13:19
May 13 (Reuters) - Senti Biosciences Inc SNTI.O :
* SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
CLINICAL
TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY
HEMATOLOGIC MALIGNANCIES INCLUDING ACUTE MYELOID LEUKEMIA
* SENTI BIOSCIENCES INC: INITIAL CLINICAL EFFICACY DATA
EXPECTED
BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025
* SENTI BIOSCIENCES INC - INITIAL CLINICAL EFFICACY DATA
EXPECTED
BY YEAR-END 2024 AND DURABILITY DATA EXPECTED IN 2025
Source text for Eikon: ID:nGNX7TWFM4
Further company coverage: SNTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates